sTUDY TYPE
RSV Modelling
Location
8 countries across 4 continents
Client
Top 10 Pharma
Client Challenge
RSV causes a substantial disease burden, typically with annual seasonality peaking in the winter months. However, its burden in adults is underestimated due to non-specific symptomatology and limited standard-of-care testing. To overcome these hurdles, model-based studies were conducted to link the variability in viral activity with the variability in an outcome that is expected to be related to RSV (e.g., bronchitis) while accounting for baseline seasonality and co-circulation of other important pathogens like influenza.
Our solution
By leveraging our expertise in modelling and RSV, P95, an expert CRO for RSV database studies, developed a generic study protocol that incorporates a model-based approach to estimate RSV-attributable hospitalisations, emergency department visits, general practitioners’ visits, and deaths. We identified potential data sources for eight selected countries of interest in Europe, North America, Oceania and Asia, and designed a questionnaire to assess the characteristics of the identified data sources. We summarised our findings and recommendations in a feasibility report.
The model-based study was piloted in two countries and implemented in the remaining six countries.
Our IMPACT
- Conducted complex database studies covering 8 countries across 4 continents
- Published generic protocol and 8 study findings in scientific journals or at scientific conferences
- Results contributed to population-level risk-benefit assessments regarding vaccine programs
As an expert CRO for RSV database studies, along with a portfolio of other infectious diseases, P95 delivers seamless, high-quality multi-country research. Let’s collaborate to advance RSV epidemiology insights – contact us today!
FAQ
Here are some answers to Frequently Asked Questions.
Why is RSV burden underestimated in adults and how does P95’s study address this?
RSV in adults tends to present with non-specific symptoms and is often under-diagnosed due to limited standard-of-care testing, so its true burden is masked. P95 uses model-based methods and secondary data sources to estimate RSV-attributable hospitalizations, ED visits, GP consultations, and deaths, accounting for seasonality and co-circulation of other pathogens.
How did P95 design the RSV database study across multiple countries?
First, P95 created a generic protocol adaptable to individual country settings. They assessed data source feasibility across eight countries on four continents via tailored questionnaires, then piloted in two countries before full rollout to the rest.
What data outputs and impact did the RSV database study deliver?
The project resulted in published findings for each country plus a generic protocol, contributing to risk-benefit assessments at population level. It gave decision makers better evidence on RSV burden to inform vaccine strategy and policy.
For what kind of clients and contexts is this RSV database modelling approach particularly useful?
It’s especially valuable for pharmaceutical sponsors, public health agencies, and regulators in countries or regions without robust prospective surveillance, where secondary data must inform vaccine program decisions, funding allocation, or public health strategy.
Request more information
Use the form below to contact us.
